Patent application number | Description | Published |
20090282413 | Scalable Scheduling of Tasks in Heterogeneous Systems - Illustrative embodiments provide a computer implemented method, a data processing system and a computer program product for scalable scheduling of tasks in heterogeneous systems is provided. According to one embodiment, the computer implemented method comprises fetching a set of tasks to form a received input, estimating run times of tasks, calculating average estimated completion times of tasks, producing a set of ordered tasks from the received input to form a task list, identifying a machine to be assigned, and assigning an identified task from the task list to an identified machine. | 11-12-2009 |
20090291448 | Prognostic and Predictive Gene Signature for Non-Small Cell Lung Cancer and Adjuvant Chemotherapy - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 11-26-2009 |
20100184063 | PROGNOSTIC AND PREDICTIVE GENE SIGNATURE FOR NON-SMALL CELL LUNG CANCER AND ADJUVANT CHEMOTHERAPY - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 07-22-2010 |
20110224313 | COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosing, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application. | 09-15-2011 |
20120004116 | METHODS FOR BIOMARKER IDENTIFICATION AND BIOMARKER FOR NON-SMALL CELL LUNG CANCER - There is provided a method for identifying a biomarker, such as a gene signature, associated with a biological parameter A 6-gene signature for non-small cell lung cancer (NSCLC) is also provided, as well as a method of prognosing or classifying a subject with non-small cell lung cancer into a poor survival group or a good survival group, using said gene signature | 01-05-2012 |
20120100999 | PROGNOSTIC GENE EXPRESSION SIGNATURE FOR SQUAMOUS CELL CARCINOMA OF THE LUNG - Provided is a gene expression signature consisting of 12 biomarkers for use in prognosing or classifying a subject with lung squamous cell carcinoma into a poor survival group or a good survival group. The 12-gene signature specific for squamous cell carcinoma consists of the biomarkers RPL22, VEGFA, G0S2, NES, TNFRSF25, DKFZP586P0123, COL8A2, ZNF3, PJPK5, RNFT2, ARHGEF12 and PTPN20A. | 04-26-2012 |
20120141603 | METHODS AND COMPOSITIONS FOR LUNG CANCER PROGNOSIS - Disclosed herein are methods and materials for prognosing survival of lung cancer patients, the methods comprising the detection of gains and losses of minimal common regions and/or genes associated with prognosis and benefit of chemotherapy. | 06-07-2012 |
20120237488 | LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER - A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis. | 09-20-2012 |
20120323594 | PROGNOSTIC AND PREDICTIVE GENE SIGNATURE FOR NON-SMALL CELL LUNG CANCER AND ADJUVANT CHEMOTHERAPY - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 12-20-2012 |
20130065789 | COMPOSITIONS AND METHODS FOR CLASSIFYING LUNG CANCER AND PROGNOSING LUNG CANCER SURVIVAL - The application provides methods of prognosmg, diagnosing, screening and classifying lung cancer patients into poor survival groups or good survival groups. A number of altered genomic regions have been identified that distinguish subtype of lung adenocarcinoma (ADC), specifically between bronchioloalveolar carcinoma (BAC) and invasive ADC with BAC features (AWBF), and genes and biomarkers whose expression are altered in individuals with pulmonary ADC according to different survival outcomes. The amplification and/or deletion of these genomic regions, and/or the biomarker expression profiles can be used to classify patients with ADC into a BAC group with excellent survival outcome, or an invasive ADC with BAC features group with higher risk of developing metastatic recurrence and poorer survival outcome. The application also includes kits for use in the methods of the application. | 03-14-2013 |
20130303826 | PROGNOSTIC SIGNATURE FOR ORAL SQUAMOUS CELL CARCINOMA - The present disclosure describes methods and compositions for diagnosing or predicting likelihood of a OSCC recurrence in a subject having undergone OSCC resection comprising: a) determining an expression level of one or more biomarkers selected from Table 4, 5 and/or 7, optionally MMP1, COL4A1, THBS2 and/or P4HA2 in a test sample from the subject, the one or more biomarkers comprising at least one of THBS2 and P4HA2, and b) comparing the expression level of the one or more biomarkers with a control, wherein a difference or a similarity in the expression level of the one or more biomarkers between the test sample and the control is used to diagnose or predict the likelihood of OSCC recurrence in the subject In particular, the present disclosure describes methods and compositions using a four-gene biomarker signature that can predict recurrence of oral squamous cell carcinoma in subjects that have histologically normal surgical resection margins. | 11-14-2013 |